Systemic amyloidosis is a group of diseases in which misfolded proteins clump into tough, insoluble fibers called amyloid and deposit in organs throughout the body, gradually destroying their structure and function. The specific protein that misfolds varies by type, which makes systemic amyloidosis not one disease but several, each with different causes, timelines, and treatments. Diagnosis is notoriously delayed, and the organs hit hardest tend to be the heart, kidneys, and nerves.
What Actually Goes Wrong
Under normal circumstances, proteins fold into precise three-dimensional shapes that let them do their jobs. In amyloidosis, something causes certain proteins to misfold and stack together into a structure scientists call the cross-beta spine: flat sheets of protein layered on top of one another and locked tightly together by interlocking side chains, a bit like a molecular zipper.1PubMed Central. Structure of the cross-beta spine of amyloid-like fibrils These sheets assemble into thin threads called protofilaments, which wind together into mature fibrils.2PubMed Central. Atomic structure and hierarchical assembly of a cross-β amyloid fibril The resulting fibrils are extremely stable and resist the body’s normal cleanup processes. When they accumulate between cells in organs like the heart or kidneys, they physically crowd out healthy tissue and interfere with the organ’s ability to work.
What makes this structure so dangerous is precisely what makes it so persistent. The tight, dry interface between the paired sheets means enzymes have almost no way in to break the fibrils apart.3PubMed Central. Paired beta-sheet structure of an Abeta(1-40) amyloid fibril revealed by electron microscopy Once amyloid deposits reach a critical mass in an organ, the damage tends to be progressive unless treatment can stop the supply of the misfolded protein at its source.
The Major Types
The type of amyloidosis depends on which protein misfolds. Three forms account for the vast majority of systemic cases, and they differ sharply in who gets them and why.
AL (Light Chain) Amyloidosis
AL amyloidosis is the most commonly diagnosed systemic form in wealthy countries. It arises from a problem in the bone marrow. A small, abnormal population of plasma cells produces an excess of misfolded immunoglobulin light chains, fragments of antibody molecules that aggregate into amyloid fibrils and deposit in tissues.4PubMed Central. Light chain (AL) amyloidosis: update on diagnosis and management The plasma cells driving AL amyloidosis have distinct genetic and molecular abnormalities, similar to those seen in other plasma cell cancers like myeloma, though the clone is often much smaller.5PubMed. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role? AL amyloidosis can affect almost any organ, but the heart, kidneys, liver, and peripheral nerves are the most common targets.
AA (Secondary) Amyloidosis
AA amyloidosis develops as a consequence of long-standing inflammation. Conditions like rheumatoid arthritis, periodic fever syndromes, and chronic infections keep the liver pumping out an inflammatory protein called serum amyloid A (SAA).6PubMed Central. Serum Amyloid A Protein-Associated Kidney Disease: Presentation, Diagnosis, and Management Over years, fragments of SAA accumulate as amyloid in organs, most commonly the kidneys. Animal research has shown that the duration before amyloid appears depends largely on how high SAA levels run; in mice engineered to produce SAA without any actual inflammation, amyloid still formed, confirming that it is the protein concentration rather than the inflammation itself that directly drives deposition.7PubMed Central. Pathogenetic mechanisms of amyloid A amyloidosis In practice, this means that effective treatment of the underlying inflammatory disease can halt or even reverse AA amyloidosis.
ATTR (Transthyretin) Amyloidosis
Transthyretin is a liver-made protein that carries thyroid hormone and vitamin A through the bloodstream. In ATTR amyloidosis, this protein becomes unstable, misfolds, and forms amyloid deposits, predominantly in the heart and peripheral nerves.8PubMed. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association There are two subtypes. In hereditary ATTR (ATTRv), a mutation in the transthyretin gene makes the protein unstable from birth, though disease usually appears in mid-adulthood and can present as polyneuropathy, cardiomyopathy, or both. In wild-type ATTR (ATTRwt), the normal, unmutated protein gradually becomes prone to misfolding with age. ATTRwt primarily causes heart failure in older adults and is increasingly recognized as a common, underdiagnosed condition. A prospective cohort study found that the median age at enrollment was about 76 years, atrial fibrillation was present in roughly two-thirds of patients, and nearly all were male.9PubMed Central. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study
ATTRwt is emerging as a surprisingly common contributor to heart failure with preserved ejection fraction (HFpEF), the form of heart failure where the heart muscle squeezes normally but fills poorly. One study of 120 HFpEF patients found that about 13% had ATTRwt on scintigraphy and biopsy confirmation, yet there were no clear clinical features that distinguished them from other HFpEF patients without targeted imaging.10European Heart Journal. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction The high degree of clinical overlap means many people with ATTRwt are currently mislabeled as having garden-variety heart failure.
Symptoms That Raise Suspicion
Amyloidosis is a great mimic. Because amyloid can deposit in nearly any organ, the symptom picture depends on which organs are involved and which type of amyloidosis is present. A scoping review of clinical features across the major types found telling differences in the earliest warning signs. In AL amyloidosis, shortness of breath and fatigue tend to appear first, along with unexplained weight loss, abdominal pain, and early satiety, clues that are often dismissed as vague or attributed to other conditions. In ATTRwt amyloidosis, carpal tunnel syndrome can precede the heart failure diagnosis by years, and preceding arrhythmias are frequently overlooked. Hereditary ATTR tends to announce itself with painful, length-dependent neuropathy in the legs and feet, unlike the sensory-loss pattern more common in AL neuropathy.11PubMed Central. Clinical features of systemic amyloidosis: a scoping review
Carpal tunnel syndrome deserves special attention as an early red flag. A study of patients undergoing carpal tunnel surgery found amyloid deposits in tenosynovial biopsy tissue in about 10% of men over 50 and women over 60 who had no previously known cause for their carpal tunnel; all positive cases had bilateral symptoms.12PubMed. Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis For anyone with bilateral carpal tunnel and unexplained heart symptoms, screening for amyloidosis is worth discussing with a doctor.
When amyloid deposits in the heart, the result is a stiff, thickened heart muscle that struggles to relax and fill properly, producing a restrictive pattern on imaging. On echocardiography, this can look like thickened walls with preserved squeezing function, sometimes mimicking hypertrophic cardiomyopathy.13PubMed. Cardiac amyloidosis: a review of the literature Kidney involvement, more common in AL and AA types, typically shows up as heavy protein loss in the urine, swelling in the legs, and progressive decline in kidney function.14Brazilian Journal of Medical and Biological Research. Renal amyloidosis: a new time for a complete diagnosis Other complications include low blood pressure, fluid around the heart or lungs, gut problems from poor absorption, and mood disorders stemming from the cumulative burden of chronic illness.15PubMed Central. Role of Palliative Care in the Supportive Management of AL Amyloidosis-A Review
Why Diagnosis Takes So Long
One of the most frustrating aspects of systemic amyloidosis is how often patients bounce between specialists before anyone thinks to test for it. A cross-sectional survey of AL amyloidosis patients found that the median person saw three providers before getting a diagnosis, and nearly 60% reported a meaningful delay. Over a third experienced delays of more than a year. About half of those who experienced delays blamed a lack of provider awareness, and roughly two-thirds felt the diagnostic process needed significant improvement.16PubMed. Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey Because amyloidosis symptoms overlap so heavily with common conditions like heart failure, kidney disease, and neuropathy, the disease rarely makes the initial differential diagnosis unless a clinician specifically considers it.
How Amyloidosis Is Diagnosed
Confirming amyloidosis requires proving that amyloid deposits are present, and then figuring out which protein is responsible. Those two steps use different tools.
The classic tissue test uses a dye called Congo red. When tissue stained with Congo red is viewed under polarized light, amyloid deposits produce a characteristic color shift that pathologists have long called “apple-green birefringence.”17PubMed Central. Origins of a pervasive, erroneous idea: The “green birefringence” of Congo red‐stained amyloid – Section: 1. INTRODUCTION: CONGO RED AS A STAIN FOR AMYLOID A biopsy of an affected organ, or sometimes of abdominal fat, provides the tissue sample. Congo red staining confirms that amyloid is there, but it does not tell you which protein formed it, and the distinction between types is critical because the treatments are completely different.
Identifying the amyloid type now relies heavily on mass spectrometry. A pathologist isolates a tiny piece of the amyloid deposit, often by laser or manual microdissection, dissolves it, and runs it through a mass spectrometer that identifies every protein present. A review of over 16,000 clinical samples confirmed that this proteomics-based approach can identify all known amyloid types in a single test, making it the current standard for accurate typing.18PubMed. Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples Newer protocols have shown that accurate typing can even be done without expensive laser equipment, using manual dissection and freely available data-processing software, which could make this capability more accessible.19PubMed Central. Tandem Mass Spectrometry-Based Amyloid Typing Using Manual Microdissection and Open-Source Data Processing
For suspected ATTR cardiac amyloidosis specifically, a nuclear medicine scan using technetium-99m pyrophosphate (PYP) has become a game-changer. It is noninvasive and, in many cases, can confirm the diagnosis without a heart biopsy. One study of a streamlined one-hour protocol showed that planar imaging had 98% sensitivity and 96% specificity for ATTR cardiac amyloidosis.20PubMed Central. Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis A positive PYP scan, combined with blood and urine tests that rule out a plasma cell disorder (to exclude AL amyloidosis), can establish a diagnosis of ATTR cardiomyopathy without tissue sampling.21PubMed Central. The use of PYP scan for evaluation of ATTR cardiac amyloidosis at a tertiary medical centre Quantitative measures from these scans may also help track disease progression or treatment response over time.22PubMed Central. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis
Treatment by Type
Because the underlying cause differs across amyloidosis types, so does the treatment approach. The basic principle is always the same: stop the supply of the misfolded protein, protect the organs already affected, and, ideally, help the body clear deposits that are already there.
Treating AL Amyloidosis
In AL amyloidosis, the misfolded light chains come from abnormal plasma cells in the bone marrow, so treatment borrows from the playbook used against myeloma and other plasma cell cancers. The landmark ANDROMEDA trial showed that adding daratumumab, an antibody that targets a protein on the surface of plasma cells, to standard chemotherapy dramatically improved outcomes. The rate of complete disappearance of the abnormal light chains was about 53% in the daratumumab group versus 18% with chemotherapy alone. Heart and kidney responses were also roughly doubled, and survival free from major organ deterioration or death favored the daratumumab group.23PubMed. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis This combination has rapidly become the standard first-line regimen for most newly diagnosed patients who are well enough to tolerate it.
Research is also exploring antibodies designed to attack the amyloid deposits themselves, rather than the cells producing the protein. Agents like CAEL-101 and dezamizumab represent this second front, aiming to accelerate the clearance of existing deposits from organs.24PubMed. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits An early proof-of-concept study showed that an anti-SAP antibody, given after depleting circulating SAP with a small-molecule drug, could trigger macrophages to engulf and clear amyloid from the liver.25PubMed. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component That concept has not yet reached routine clinical use, but it represents a fundamentally different approach from simply stopping new protein production.
Treating ATTR Amyloidosis
For ATTR amyloidosis involving the heart, the biggest advance has been tafamidis, a small molecule that stabilizes the transthyretin tetramer and prevents it from falling apart into misfolding-prone subunits. In its pivotal trial, tafamidis reduced all-cause mortality compared with placebo (about 30% versus 43% over 30 months) and cut cardiovascular hospitalizations by roughly a third.26PubMed. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy A post hoc analysis confirmed that tafamidis also slowed the deterioration of heart function itself, preserving both the heart’s ability to squeeze and to relax.27JAMA Cardiology. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial Long-term follow-up extending to nearly five years showed a sustained survival benefit: death occurred in about 45% of patients who received tafamidis continuously versus about 63% of those who started on placebo and crossed over later, highlighting the advantage of early treatment.28PubMed Central. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
A separate class of treatments goes further upstream. Gene-silencing drugs, including the siRNAs patisiran and vutrisiran and the antisense oligonucleotide inotersen, block the liver from producing transthyretin altogether. All three are approved for ATTR polyneuropathy, and emerging data suggest they may also benefit heart involvement.29PubMed Central. RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis The existence of both stabilizer and silencer approaches gives clinicians some flexibility in tailoring treatment to the individual patient’s dominant symptoms.
Treating AA Amyloidosis
In AA amyloidosis, the treatment target is the inflammatory disease that keeps SAA levels elevated. Aggressively controlling rheumatoid arthritis with modern biologics, for example, or clearing a chronic infection can dramatically reduce the amount of SAA the liver produces. When SAA levels drop and stay low, existing amyloid deposits can slowly regress and kidney function may stabilize or improve. There is no drug specifically approved for AA amyloidosis itself; the strategy is entirely about eliminating the inflammatory fuel.
Prognosis and How Doctors Gauge Severity
Survival in systemic amyloidosis varies enormously depending on the type, the organs involved, and how advanced the disease is at diagnosis. For AL amyloidosis, the heart is the critical prognostic organ. A widely used staging system combines two cardiac blood markers, cardiac troponin T and NT-proBNP, with a measure of the circulating abnormal light chains. Patients are sorted into four stages. In the original validation, median survival ranged from about 94 months for stage I down to under 6 months for stage IV.30PubMed Central. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements That enormous gap underscores why early diagnosis matters so much: catching the disease before significant cardiac damage translates into years of additional life.
The same cardiac biomarkers double as treatment-response indicators. If the abnormal light chains drop sharply and NT-proBNP improves within the first few months of therapy, prognosis improves correspondingly. Researchers have formalized this into response criteria with four tiers based on how completely the amyloidogenic light chains are suppressed, and changes in both light chains and NT-proBNP can predict survival as early as three months after starting treatment.31PubMed. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes This fast feedback loop lets doctors know relatively quickly whether the chosen regimen is working or whether a switch is needed.
Supportive Care and Quality of Life
Even when disease-directed therapy is working, the day-to-day burden of living with amyloidosis can be heavy. Organ damage already present at diagnosis does not vanish overnight, and the treatments themselves can be taxing. Effective supportive care is essential not just for comfort but for keeping patients well enough to continue receiving therapy.32PubMed Central. Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Heart failure from amyloidosis is managed with careful diuretic use to control fluid overload, though the usual heart failure drugs like ACE inhibitors and beta-blockers are often poorly tolerated because amyloid-affected hearts depend on a fast heart rate and adequate filling pressures to maintain output. Low blood pressure is a frequent problem, sometimes requiring patients to wear compression garments and increase salt and fluid intake, the opposite of standard heart failure advice. Kidney involvement may ultimately require dialysis. Gastrointestinal amyloid can cause poor nutrient absorption, nausea, and severe weight loss. Pain from neuropathy can be persistent and require specialized management. Because the combination of chronic disease, debilitating symptoms, and intensive treatment regimens takes a psychological toll, screening for depression and anxiety is an important part of comprehensive care.15PubMed Central. Role of Palliative Care in the Supportive Management of AL Amyloidosis-A Review
Local Versus Systemic Disease
Not all amyloid deposits mean systemic disease. Amyloid can occasionally form in a single site, such as the lungs, bladder, or skin, without involving the rest of the body. The distinction matters enormously for prognosis and treatment. A study comparing localized and systemic pulmonary AL amyloidosis found that the localized form had dramatically better ten-year disease-specific survival, about 96% compared with roughly 52% for systemic involvement. Localized disease often shows a nodular pattern on CT scanning and can frequently be managed conservatively, whereas systemic AL amyloidosis requires aggressive chemotherapy-based treatment.33PubMed. Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management A biopsy confirming amyloid in one spot does not automatically mean a person has systemic amyloidosis, but it does demand a thorough workup to determine whether deposits exist elsewhere.
Emerging Research Directions
The treatment landscape for systemic amyloidosis has changed more in the last decade than in the previous fifty years combined, and several promising research avenues remain active. Gene-editing approaches, including CRISPR-based strategies, are being explored for hereditary ATTR amyloidosis. Early clinical data from a single-dose CRISPR treatment showed profound and durable reductions in circulating transthyretin, raising the possibility that a one-time therapy could replace lifelong injections or pills. Antibodies that directly target and clear deposited amyloid, rather than simply halting new deposition, are in various stages of clinical trials across both AL and ATTR forms. And for AA amyloidosis, the expanding arsenal of biologics for inflammatory diseases means that the root cause can be controlled more effectively than ever, potentially making this form increasingly preventable.
One of the biggest practical shifts is in awareness. As diagnostic tools like the PYP scan and mass spectrometry-based typing become more widely available, and as physicians outside amyloidosis specialty centers learn to recognize the early warning signs, the diagnostic delay that currently costs patients months or years of treatable time should narrow. For anyone dealing with unexplained heart failure, kidney protein loss, or bilateral carpal tunnel syndrome, especially in combination, asking whether amyloidosis has been considered is a reasonable and potentially life-altering question to raise with a doctor.